Liquidia Technologies, Inc.
(NASDAQ : LQDA)

( )
LQDA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-0.14%42.140.9%$1171.26m
JNJJohnson & Johnson
-0.68%135.420.6%$1013.93m
MRKMerck & Co., Inc.
0.50%79.830.6%$960.31m
LLYEli Lilly and Company
0.06%122.731.0%$930.36m
BMYBristol-Myers Squibb Company
-2.24%50.151.4%$745.64m
ABBVAbbVie, Inc.
-1.56%78.742.2%$653.71m
AZNAstraZeneca PLC Sponsored ADR
-0.25%40.431.3%$195.97m
NVSNovartis AG Sponsored ADR
-0.25%90.510.2%$190.13m
GSKGlaxoSmithKline plc Sponsored ADR
-0.55%40.540.2%$137.36m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.08%49.660.1%$72.90m
SNYSanofi Sponsored ADR
-1.95%41.330.2%$36.89m
LCILannett Company, Inc.
-4.69%9.3437.0%$16.14m
AKTXAkari Therapeutics Plc Sponsored ADR
1.07%1.891.7%$0.06m
EPIXESSA Pharma Inc
-5.33%3.550.1%$0.05m

Company Profile

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. The collaborates with leading pharmaceutical companies to apply its PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.